Catalog snapshot
- 6Human RCT*
- 2Human other
- 31Animal
- 3In vitro
- 12Review
- 0Syst. review
- 24Other
- 78Total
- 3Registered trials
*Record counts by study type from the PHX research catalog (PubMed, ClinicalTrials.gov, Europe PMC). Human RCT counts include registry entries. Labels are auto-classified from abstracts.
What the Research Suggests, in Plain Language
CJC-1295 and ipamorelin are two separate lab-made compounds that prompt the body to release growth hormone. Neither is approved, and no study has tested them together.
- In people, a small early-stage study of CJC-1295 in healthy adults reported that growth hormone levels stayed raised for days, with no serious side effects reported over the short study.
- In people, a larger trial of ipamorelin after bowel surgery found no clear difference from a placebo on its main goal, faster return of normal digestion.
- In animal studies, mostly in rats, results suggest ipamorelin may be linked to bone growth, and in rats given steroid drugs, to less loss of muscle strength and bone formation.
In short: development of both compounds stopped at mid-stage human trials. These results do not show that either compound, or the two together, is safe or effective in people.
Overview
CJC-1295 and ipamorelin are separate investigational compounds that act on the growth hormone system. Neither is an approved drug. Both development programs stopped at phase 2.
What the Research Actually Presents
CJC-1295 phase 1 (JCEM 2006, healthy adults; PMID 16352683): Sustained increases in growth hormone (GH) and insulin-like growth factor 1 (IGF-1) were reported. No serious adverse reactions in the short-term study. A follow-up study reported that GH was still released in pulses (PMID 17018654).
Ipamorelin phase 2 randomized controlled trial (RCT) in postoperative ileus (114 patients; PMID 25331030): No significant difference from placebo on the primary endpoint.
Animal studies (~31 records, including Danish groups 1998–1999; several are horse or doping-detection method papers rather than biology studies):
- Glucocorticoid (steroid) models: In adult rats given glucocorticoids, ipamorelin co-administration was reported to counteract decreases in muscle strength and bone formation (PMID 11735244). Other rat studies examined bone growth (PMID 10373343).
- Postoperative ileus models: Animals showed changes in gastrointestinal motility measures in the models tested.
No studies of the combination are identified. A CJC-1295 phase 2 trial in HIV and obesity was terminated (NCT00267527).
What the Research Suggests
Early human data for CJC-1295 reported increases in GH and IGF-1. The ipamorelin ileus trial did not meet its primary endpoint.
In animal models, ipamorelin was associated with muscle-strength, bone and gastrointestinal motility observations under the conditions tested. No combination data exist.
Mechanism and Signaling Pathways (as described in the literature)
CJC-1295 is described as a long-acting growth hormone-releasing hormone (GHRH) analog stimulating GH release. Ipamorelin is described as a selective ghrelin receptor agonist (it acts on the receptor for the hunger hormone ghrelin). Descriptions come from early-phase and animal work.
Research Landscape
Catalog: 78 records — 6 human randomized controlled trials (RCTs, including registry entries), 2 other human, 31 animal, 3 in-vitro, 12 reviews, 0 systematic reviews/meta-analyses, 24 other. Many of the remaining records are anti-doping detection methods.
Key Studies
- Teichman SL et al. 2006 (JCEM): phase 1 study of CJC-1295 in healthy adults (PMID 16352683).
- Ionescu M et al. 2006 (JCEM): follow-up study of GH pulse patterns with CJC-1295 (PMID 17018654).
- Beck DE et al. 2014 (Int J Colorectal Dis): phase 2 randomized, placebo-controlled trial of ipamorelin in postoperative ileus; 114 patients (PMID 25331030; NCT00672074).
- Andersen NB et al. 2001: animal study (rats), glucocorticoid model (PMID 11735244).
- Raun K et al. 1998: animal pharmacology (rats, pigs) (PMID 9849822).
- Registered trials: NCT00267527 (CJC-1295 phase 2, terminated), NCT01280344 (ipamorelin phase 2, completed, no results posted).
Safety Findings Reported in the Studies
Phase 1 CJC-1295 reported no serious adverse reactions in the short term. In the ipamorelin ileus trial, adverse-event rates were similar in the ipamorelin and placebo groups (PMID 25331030).
Limitations and Evidence Gaps
No studies of the combination. Both programs stopped at phase 2.
Regulatory Status
Neither is approved. Both prohibited by the World Anti-Doping Agency (WADA).
References
Teichman SL et al. 2006 (PMID 16352683). Ionescu M et al. 2006 (PMID 17018654). Beck DE et al. 2014 (PMID 25331030). Andersen NB et al. 2001 (PMID 11735244). Johansen PB et al. 1999 (PMID 10373343). Raun K et al. 1998 (PMID 9849822). Registered trials NCT00672074, NCT01280344, NCT00267527. Animal studies in the catalog.
Evidence reviewed through November 2026 (PHX research catalog snapshot of PubMed, ClinicalTrials.gov and Europe PMC).
Frequently Asked Questions
Are there human studies on CJC-1295 and ipamorelin?
Each compound has early-stage human data: a phase 1 study of CJC-1295 in healthy adults (PMID 16352683) and a phase 2 trial of ipamorelin after bowel surgery that did not meet its primary endpoint (PMID 25331030). No study has tested the two together.
Are CJC-1295 or ipamorelin FDA approved?
No. Neither compound is approved, and both are prohibited by the World Anti-Doping Agency.
Why did development stop?
The catalog records show both programs stopped at phase 2; a CJC-1295 phase 2 trial was terminated (NCT00267527). The publications do not give a single reason.
Answers summarize the PHX research catalog and are not medical advice.
Linked sources
Records from the PHX research catalog that correspond to the studies discussed above. Links open PubMed or ClinicalTrials.gov.
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
- Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog
- Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients
- Ipamorelin, the first selective growth hormone secretagogue
- Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats
- The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats
- A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 2 Study to Evaluate the Efficacy and Safety of CJC 1295 Administered for 12 Weeks in HIV Infected Patients With HIV Associated Visceral Obesity
- A Phase II, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety and Efficacy of Ipamorelin Compared to Placebo for the Management of Post-Operative Ileus in Patients
- Phase II Double-Blind Placebo-Controlled Dose Finding Study to Evaluate Safety/Efficacy of Ipamorelin Compared to Placebo for Recovery of Gastrointestinal Function in Patients Following Small or Large Bowel Resection w/Primary Anastomosis